ARA-290 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
ARA-290 is typically reconstituted with bacteriostatic water (BAC water). The standard dosage of 2-4 mg daily is administered once daily via subcutaneous injection. Use our peptide calculator for exact mixing ratios.
How Do You Reconstitute ARA-290?
ARA-290 is supplied as a lyophilized (freeze-dried) powder that must be reconstituted before use. Proper reconstitution is critical for accurate dosing and maintaining stability.
This guide covers the step-by-step process for mixing ARA-290 with bacteriostatic water to achieve your target concentration.
What Supplies Do You Need?
To reconstitute ARA-290, you need: the ARA-290 vial (lyophilized powder), bacteriostatic water (BAC water with 0.9% benzyl alcohol), insulin syringes (typically 1mL/100-unit), alcohol swabs, and a clean workspace.
Important: Always use bacteriostatic water — not sterile water or saline. BAC water's benzyl alcohol prevents bacterial contamination, extending the usable life of reconstituted ARA-290 to 4-6 weeks.
Step-by-Step ARA-290 Reconstitution
Step 1: Clean the vial tops of both the ARA-290 and BAC water with alcohol swabs.
Step 2: Draw the calculated amount of BAC water into an insulin syringe. Use our peptide calculator to determine the exact amount.
Step 3: Insert the needle into the ARA-290 vial at an angle, and let the water run down the side of the glass — never spray directly onto the powder as this can damage the peptide bonds.
Step 4: Gently swirl (do not shake) the vial until the powder is fully dissolved. The solution should be clear.
Step 5: Label the vial with the date and concentration. Store at 2-8°C.
Calculate Your ARA-290 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for ARA-290.
Open Calculator →How Do You Dose Reconstituted ARA-290?
After reconstitution, the standard ARA-290 dose is 2-4 mg daily administered once daily via subcutaneous injection. The number of units on your insulin syringe depends on how much BAC water you added.
Our calculator will tell you exactly how many units to draw for your dose based on your specific reconstitution ratio.
How Do You Store Reconstituted ARA-290?
Store reconstituted ARA-290 at 2-8°C (standard refrigerator temperature). Use within 4-6 weeks. Keep away from light and temperature fluctuations.
Unreconstituted ARA-290 powder can be stored at -20°C for 12+ months. Once you reconstitute it, the clock starts.
Bottom Line
Reconstituting ARA-290 is straightforward — add BAC water, swirl gently, refrigerate. The key is using the right amount of water for accurate dosing. Use our peptide calculator every time.
Complete Guide
ARA-290 : Benefits, Dosage, Side Effects & Research
Related Reading
- ARA-290 Dosage Guide
- ARA-290 Benefits
- ARA-290 Side Effects
- ARA-290 Stacking Guide
- ARA-290 Cycle Guide
- ARA-290 Research
Research-Grade Sourcing
If you're going to research ARA-290, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages: 2-4 mg daily administered once daily via subcutaneous injection. Cycle length: 28 days typical; 8-16 weeks for extended response. Half-life: approximately 24 hours. Use our peptide calculator for exact reconstitution math.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 safe?
ARA-290 has shown a preliminary safety profile in research. Investigational. Underwent Phase II clinical trials. Not FDA-approved. All research should follow appropriate safety protocols.